Clinical Trial Update: A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of cannabidiol oral solution in Rett syndrome was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• Cannabidiol Oral Solution (GWP42003-P, CBD-OS) (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Rett Syndrome, RTT | Phase 3 | Status: TERMINATED | Results posted: 2022-08-08